Skip to main content
Eurobio Scientific logo

Eurobio Scientific — Investor Relations & Filings

Ticker · ALERS ISIN · FR0013240934 LEI · 969500IQEUEH806GE257 PA Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2026-04-29 Report Publication Anno…
Country FR France
Listing PA ALERS

About Eurobio Scientific

https://www.eurobio-scientific.com

Eurobio Scientific is an integrated company specializing in in vitro diagnostics (IVD). Its activities cover the entire value chain, from research and development to the manufacturing and commercialization of specialty diagnostic products. The company's core focus areas are transplantation, oncology, and infectious diseases. In transplantation, it provides reagents, software for transplant matching and chimerism monitoring, and culture media for cornea grafts. For oncology, it develops and manufactures prognostic genomic tests for breast and prostate cancer. The group also markets a comprehensive portfolio of molecular tests for detecting infectious diseases, alongside solutions for immunology, fertility, and dermatological conditions.

Recent filings

Filing Released Lang Actions
EUROBIO SCIENTIFIC : MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
Report Publication Announcement Classification · 95% confidence The document is a press release titled “MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025” announcing that the annual financial report has been made available to the public and filed with the AMF. It provides a link to the report on the company website and sets a date for the AGM. It does not contain the actual financial statements or detailed report content but simply announces its publication. Under the “Menu vs Meal” rule, a short announcement stating that the report is available online classifies as a Report Publication Announcement (RPA).
2026-04-29 French
Eurobio Scientific signe un accord définitif en vue de l'acquisition de la division « Lab Products » de CareDx dédiée à la transplantation
M&A Activity Classification · 90% confidence The document is a press release announcing a definitive agreement for Eurobio Scientific to acquire the Lab Products division of CareDx. It details transaction terms, strategic rationale, purchase price, and closing conditions, which aligns with an M&A activity announcement rather than an annual report, earnings release, or management notice. Therefore, it should be classified under M&A Activity (Code: TAR).
2026-04-16 French
Eurobio scientific signs definitive agreement to acquire CareDx’s transplant Lab Product division
M&A Activity Classification · 90% confidence The document is a corporate press release announcing a definitive agreement to acquire CareDx’s Lab Products division. It details the strategic rationale, transaction terms, and parties involved, characteristic of an M&A announcement. This aligns with the M&A Activity category (Code: TAR).
2026-04-16 English
EUROBIO SCIENTIFIC : RESULTAT ANNUEL 2025
Earnings Release Classification · 92% confidence The document is a press release dated April 10, 2026, titled “RESULTAT ANNUEL 2025” and provides summarized full-year 2025 financial results (revenues, margins, net income), key highlights, and outlook. It is not the full statutory annual report but an initial public announcement of annual financial results. Therefore, it fits the definition of an Earnings Release (initial announcement of periodical financial results). FY 2025
2026-04-10 French
EUROBIO SCIENTIFIC : 2025 ANNUAL RESULTS
Earnings Release Classification · 92% confidence The document is a press release summarizing the company’s consolidated annual results for 2025, with key financial highlights (revenue growth, margins, net income) and strategic commentary. It is not the full Annual Report (10-K) nor an announcement that a report has been published, but rather an initial announcement of year-end financial performance. This matches the definition of an Earnings Release. FY 2025
2026-04-10 English
Eurobio Scientific : chiffre d'affaires 2025
Earnings Release Classification · 100% confidence The document is a press release from Eurobio Scientific announcing its annual revenue figures for the fiscal year 2025. It provides key financial highlights, such as the 9% revenue growth, breakdown of revenue by product type and geography, and mentions of recent acquisitions. It explicitly states that the full annual results will be released on April 10, 2026. Since this is an initial announcement of financial results (key highlights only) rather than the full audited annual report, it is classified as an Earnings Release. FY 2025
2026-01-27 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.